Business Wire

Metr: Crowdfunding to Combat Rising Energy Costs

30.9.2025 16:07:00 CEST | Business Wire | Press Release

Share

Landlords and tenants are facing tough times at the start of the new heating season: heating and CO2 costs are forecast to rise significantly. At the same time, the EU has revised its Buildings Directive. The building sector must reduce its CO2 emissions to meet climate targets. Berlin-based PropTech company metr offers a solution for greater energy efficiency without extensive building restoration: digital heating optimization enables energy savings of up to 35 percent in existing building stock.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930569771/en/

Private individuals can support the development of energy efficiency solutions for existing buildings while benefiting as investors from the company’s increasing value. metr develops technologies that make buildings up to 35% more efficient – a cost-effective alternative to expensive building renovations. Nearly 70 organizations, including Deutsche Telekom, the German Red Cross, and Median Kliniken, already rely on the digital solutions used in 3,600 buildings with more than 100,000 rental units.

"Most buildings still waste energy because they lack smart, affordable solutions to optimize their heating systems, which account for approximately 80 percent of buildings' energy consumption. This stands in contrast to the EU's ambitious climate targets,“ explains Dr. Franka Birke, Managing Director, metr. ”The metr plug-and-play technology provides real-time energy information and optimizes heating systems in existing buildings fully automated, using AI-powered software. This leads to an immediate reduction in energy costs and CO2 emissions."

A crowdfunding campaign is now driving the European expansion of the platform technology, which is already successful in Germany. More than 70 companies – including Deutsche Telekom, the German Red Cross, and Median Kliniken – already rely on metr software. metr has raised more than 5 million Euro in equity capital as part of a first closing. As part of the second closing of this Series B, a further 1.5 million Euro is to be raised, including via the crowdfunding platform Invesdor.

Energy efficiency offers economic potential

The timing for investors could hardly be better: As energy prices continue to rise and the EU prepares stricter efficiency requirements for the real estate industry, property owners are looking for fast, scalable solutions to reduce heating and operating costs.

Until October 9, investors can join a growing technology company that is contributing measurably to the energy transition. The advantages are:

  • Contribution to reducing energy costs and CO2 emissions, and to achieving several UN sustainability goals
  • Growing demand for smart building technology
  • Scalability and internationalization based on 3,600 properties already under contract in Germany
  • Future-proof, automated technology
  • Software-as-a-Service and Equipment-as-a-Service business models for long-term revenue

About

The Berlin based company metr develops data-driven solutions for reliable, efficient and secure building management.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930569771/en/

Contacts

Victoria Berndt
Director Marketing & Communications
victoria.berndt@metr.systems

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye